Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups

Area of Science:

• Hematology
• Oncology

Background:

• Chronic myelomonocytic leukemia (CMML) is a heterogeneous clonal hematopoietic stem cell disorder.
• Effective management strategies require clear guidelines based on clinical relevance.

Purpose of the Study:

• To develop evidence-based recommendations for the diagnosis and management of CMML.
• To provide guidance on patient evaluation, risk stratification, and therapeutic approaches.

Main Methods:

• A Delphi process and consensus conferences involving Italian hematology experts.
• Selection of key clinical questions and development of consensus statements.

Main Results:

• Recommendations stratified by CMML subtype (myelodysplastic vs. myeloproliferative) and bone marrow blast percentage.
• Specific first-line therapies suggested: supportive care for low-blast MDS-type, 5-azacytidine for high-blast MDS-type, hydroxyurea for low-blast MPN-type, and polychemotherapy for high-blast MPN-type.
• Allogeneic stem cell transplantation recommended within clinical trials for selected patients.

Conclusions:

• The guidelines offer a structured approach to CMML management.
• Tailored therapeutic strategies are crucial for optimizing patient outcomes in CMML.